A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Antimicrobial Peptide PL-5 Topical Spray in Patients With Mild Infections of Diabetic Foot Ulcers
Latest Information Update: 30 May 2025
At a glance
- Drugs Peceleganan
- Indications Diabetic foot ulcer; Skin and soft tissue infections
- Focus Therapeutic Use
- Sponsors Jiangsu ProteLight Pharmaceutical and Biotechnology
Most Recent Events
- 30 May 2025 Planned End Date changed from 30 Dec 2027 to 30 Apr 2027.
- 24 Sep 2024 Planned End Date changed from 30 Jun 2025 to 30 Dec 2027.
- 24 Sep 2024 Planned primary completion date changed from 30 Dec 2024 to 30 Dec 2026.